(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote by the Federal Trade Commission (FTC): “We agree with the Federal Trade Commission’s acknowledgement that market dynamics for pharmacy benefit companies have changed over
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, released a new episode, “Understanding Prescription Drug Rebates.” The podcast episode, hosted by PCMA President and CEO JC Scott, features Alex Brill, a health policy researcher and founder
EVP and President, Elixir Chris DuPaul is a member of the executive leadership team for Rite Aid Corporation for Elixir Solutions, the company’s pharmacy benefit management (PBM) business. As EVP and President of Elixir, Chris leads day-to-day operations across commercial
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked Members of Congress a critical question in a new op-ed published in Townhall: Congress wants
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics that increase prescription drug costs for patients. The report, conducted by the research firm Visante,
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug companies retain the great majority of the prescription drug dollar. What is the prescription drug
(Washington, D.C.) — Today, representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; pharmacies and pharmacists across all practice settings, including health systems and hospitals, community, specialty, and managed care; supermarkets; wholesalers; pharmaceutical
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending,” authored by University of Chicago Professor of
(Washington, D.C.) — PCMA issued the following statement on legislation introduced in the House of Representatives: Legislation introduced in U.S. House of Representatives targeting pharmacy benefits would do nothing to reduce the cost of prescription drugs for patients and would
©2024 PCMA. All Rights Reserved.
